Role of Notch signaling pathway in gastric cancer pathogenesis

Wspolczesna Onkologia

Volumn 17, Issue 1, 2013, Pages 1-5

  Brzozowa, Marlena ^a,b   Mielanczyk, Lukasz ^a   Michalski, Marek ^a   Malinowski, Lukasz ^a   Kowalczyk Ziomek, Grazyna ^a   Helewski, Krzysztof ^a   Harabin Slowinska, Marzena ^a   Wojnicz, Romuald ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Doctoral School of Medical University of Silesia   (Poland)

Author keywords

secretase inhibitors; COX 2; Gastric cancer; MiR 34; Notch

Indexed keywords

DELTA LIKE 1; DELTA LIKE 3; DELTA LIKE 4; JAGGED1; JAGGED2; MEMBRANE PROTEIN; MICRORNA; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL FATE; NOTCH SIGNALING PATHWAY; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS;

EID: 84876274335     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.33765     Document Type: Review

References (37)

1. Klusek J, Głuszek S, Kozieł D. Co nowego wprofilaktyce nowotworów układu pokarmowego-przegla̧d piśmiennictwa 2009-2010. Przegl Gastroenterol 2011; 6: 78-84.
2. Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastr Hep 2006; 4: 416-25.
3. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-9.
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on agregate date. J Clin Oncol 2006; 24: 2903-9.
5. Staniuk T, Jankowski M, Zegarski W, Małkowski B, Kula Z. Ocena przydatności badania FDG-PET/CT wdiagnostyce i kwalifikacji do leczenia operacyjnego zaawansowanego raka żoła̧dka. Wspolczesna Onkol 2010; 14: 302-9.
6. Nowara E, Boratyn-Nowicka A, Polakiewicz-Gilowska A, Drosik A, Kustra M, Huszno J. Chemotherapy for gastric cancer patients-time for personalization in medicine? Wspolczesna Onkol 2012; 16: 86-89.
7. Huszno J, Mrochen-Domin I, Zembala-Nożyńska E, Tukiendorf A, Lange D, Nowara E. Mucin secretion activity of gastric cancer as a prognostic factor: A clinicopathological analysis. Wspolczesna Onkol 2012; 16: 159-64.
8. Koch U, Radtke F. Notch and cancer: A double-edged sword. Cell Mol Life Sci 2007; 64: 2746-2762.
9. Borgrefe T, Oswald F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66: 1631-46.
10. Kopan R, Ilagan MX. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 2009; 137: 216-33.
11. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223-33.
12. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S, Grande E. Notch signaling in cancer stem cells. Clin Transl Oncol 2009; 11: 11-9.
13. Kang H, An HJ, Song JY, Kim TH, Heo JH, Ahn DH, Kim G. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology 2012; doi: 10.1111/j.1365-2559.2012.04274.x.
14. Sun Y, Gao X, Liu J, et al. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Arch Pathol Lab Med 2011; 135: 451-8.
15. Wang Z, Li Y, Sarkar FH. Notch signaling proteins: Legitymate targets for cancer therapy. Curr Protein Pept Sci 2010; 11: 398-408.
16. Piazzi G, Fini L, Selgrad M, et al. Epigenetic regulation of Delta-Like 1 controls Notch1 activation in gastric cancer. Oncotarget 2011; 2: 1291-301.
17. Yeh TS, Wu CW, Hsu KW, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 2009; 69: 5039-48.
18. Hsu KW, Hsieh RH, Huang KH. Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression. Carcinogenesis 2012; 33: 1459-67.
19. Tseng YC, Tsai YH, Tseng MJ, et al. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog 2012; 51: 939-51.
20. Wang Z, Aamir YL, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 2010; 1806: 258-67.
21. Miele L. Notch signaling. Clin Cancer Res 2006; 12: 1074-9.
22. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008; 27: 5124-31.
23. Shih I, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007; 67: 1879-82.
24. Mao XY, Wang XG, Lu XJ, Xu L, Hang CB. COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray. World J Gastroenterol 2007; 13: 3466-71.
25. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shio-zaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-5.
26. Fosslien E. Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31: 325-48.
27. Ji Q, Hao X, Meng Y, Zhang M, DeSano J, Fan D, Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266-78.
28. Wang Z, Li Y, Sarkar FH. Notch signaling proteins: Legitymate target for cancer therapy. Curr Protein Pept Sci 2010; 11: 398-408.
29. Bommer GT, Gerin I, Feng Y, et al. P53-mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol 2007; 17: 1298-307.
30. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-52.
31. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 2009; 388: 35-40.
32. Kato M, Paranjape T, Muller RU, et al. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 2009; 28: 2419-24.
33. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumorsuppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
34. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008; 105: 13556-61.
35. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008; 68: 4123-32.
36. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Mens-sen A, Meister G, Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6: 1586-93.
37. Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, Fazlul H, Sarkar FH. Crosstalk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 2010; 292: 141-8.